Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Triple-negative breast cancer (TNBC) is a particularly aggressive type of breast cancer that is difficult to treat. Unlike other forms of breast cancer, TNBC tends to relapse earlier and spread more quickly to other parts of the body. Unfortunately, patients with TNBC have a lower survival rate, often less than five years after diagnosis. This highlights the urgent need for better treatments for TNBC. One of the main challenges in treating TNBC is that it lacks certain receptors that other breast cancers have. These receptors are usually targeted by specific therapies, making TNBC harder to treat with targeted approaches. Currently, a type of imaging called \[18F\]FDG PET/CT is the most accurate method for detecting breast cancer and its spread. However, with the rise of personalized medicine, there is a growing interest in molecular targeted approaches. These methods aim to provide highly specific diagnostics and treatments based on the unique characteristics of each patient's cancer. One promising target for these new approaches is a receptor called CXCR4. CXCR4 is found on the surface of many cells and is involved in various processes in the body. It is often overexpressed in different types of cancer, including breast cancer. Research has shown that CXCR4 levels are higher in metastatic sites (where cancer has spread) compared to primary tumors. CXCR4 is not only present in cancer cells but also in immune cells within the tumor environment. In invasive breast cancer, CXCR4 plays a crucial role in tumor migration, invasiveness, metastasis, and proliferation. A clinical study evaluated 18 breast cancer patients using a new imaging method called \[68Ga\]Ga-PentixaFor PET/CT or PET/MR. They found that this method showed higher uptake in breast cancer cases with poorer prognosis compared to the traditional \[18F\]FDG PET/CT. Higher CXCR4 expression is particularly seen in TNBC compared to other breast cancer subtypes. The goal of the study is to assess how \[68Ga\]Ga-PentixaFor is distributed in the body using PET/CT imaging. This will help demonstrate the potential of CXCR4 as a promising target for new treatments. If successful, \[68Ga\]Ga-PentixaFor PET/CT could become a valuable tool for identifying patients who might benefit from treatments using \[177Lu\]/\[90Y\] PentixaTher.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pisemna zgodę pacjenta na udział w badaniu.
- •Wiek co najmniej 18 lat.
- •Potwierdzony histologicznie rak piersi potrójnie negatywny (bez receptorów estrogenowych, progesteronowych i HER2).
- •Przerzuty raka piersi z co najmniej jednym zmierialnym guzem potwierdzonym badaniem PET/CT.
- •Dobrze funkcjonujący układ immunologiczny (wynik ECOG < 2).
- •Negatywny test ciąży u kobiet w wieku rozrodczym.
- •Prawidłowa funkcja nerek i wątroby potwierdzona badaniami laboratoryjnymi.
- •Ważne ubezpieczenie zdrowotne i gotowość do pozostania w badaniu przez cały czas trwania.
✗ Disqualifies
- •Inny nowotwór w ciągu ostatnich 3 lat przed badaniem (z wyjątkiem raka podstawnokomórkowego).
- •Niemożliwość pozostania nieruchomym przez co najmniej 1 godzinę lub klaustrofobia.
- •Poważna choroba nie nowotworowa, która może wpłynąć na bezpieczeństwo lub wyniki badania.
- •Zaburzenia psychiczne uniemożliwiające wyrażenie świadomej zgody.
- •Ciąża, możliwość ciąży lub karmienie piersią.
- •Wysoki poziom cukru we krwi (> 12 mmol/L).
- •Poważne osłabienie nerek (GFR ≤ 45 mL/min/1,73 m²).
- •Uczulenie na substancje czynne badania lub jego składniki.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Institut de cancerologie de l'Ouest
Saint-Herblain, France
Trial contact
CAROLINE ROUSSEAU, MD, PhD
NADIA ALLAM, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.